ATTR amyloidosis in patients undergoing transcatheter aortic valve replacement: from prevalence to hemodynamic consequence.

Recruiting

• Conditions: Tevens aandoeningen van hey myocard (amyloidoseophoping).; Amyloidosis; protein misfolding disease; 10046973

• Registration Number: NL-OMON55157
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 340

Inclusion Criteria

Severe symptomatic aortic valve stenosis

Exclusion Criteria

- Unable to undergo scintigraphy

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Main study parameters/endpoints:<br /><br>1. Prevalence of ATTR, measured by bone scintigraphy, in patients undergoing<br /><br>TAVR.<br /><br>2. Differences in acute hemodynamic response to TAVR between ATTR and non-ATTR<br /><br>patients. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. To determine the influence (relative contribution) of ATTR to the LV<br /><br>dysfunction in patients with AS undergoing TAVR.<br /><br>2. To determine whether ATTR influences the effectiveness of TAVR treatment on<br /><br>improvement in Quality of Life.<br /><br>3. To determine whether ATTR influences survival and future hospitalizations<br /><br>rate after TAVR treatment<br /><br>4. To determine possible predictors of the presence of ATTR, using<br /><br>echocardiography and biomarkers. </p><br>